The Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes in the Real World Setting (VEDO TDM RWE)
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Biomarker; Therapeutic Use
- Acronyms VEDO TDM RWE
- Sponsors Takeda
- 11 Jun 2021 Status changed from active, no longer recruiting to completed.
- 08 Mar 2021 Planned End Date changed from 31 Mar 2021 to 31 Jul 2021.
- 14 Oct 2020 Status changed from not yet recruiting to active, no longer recruiting.